SARASOTA, Fla., Feb. 23 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) today announced the introduction of its new DNAWitness(TM) testing kit utilizing the Company's proprietary DNAWitness(TM) forensics technology for the law enforcement market, the only testing method available with predictive capability that can identify the percentage of a person's genetic makeup. "The kit is a natural progression of the Company's DNAWitness(TM) testing service, which previously was only performed at DNAPrint's Sarasota laboratory, and will enable forensics experts to conduct their own tests in their own facilities," stated Richard Gabriel, the Company's President and Chief Executive Officer. "We anticipate that by making DNAWitness(TM) directly available to law enforcement agencies, the kit will lead to more rapid integration of our technology into the global forensics market and we expect it to be a significant revenue source for the Company. At the same time, we will continue to build on our established DNAWitness(TM) custom services at our own facilities to clients who prefer to outsource their DNA laboratory work." DNAWitness(TM) forensics technology analyzes DNA recovered at a crime scene and provides the percentage of Bio-Geographical Ancestry (BGA) makeup among four possible genetic groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European, narrowing the list of potential suspects that investigators are seeking in connection with a crime. "The kit puts the power of DNAPrint's forensics technology directly into the hands of local crime scene investigators," stated Zach Gaskin, DNAPrint's Technical Coordinator of Forensics. "It also is a valuable time- and cost- saving investigative tool because it reduces the number of false leads that detectives normally would have to chase. In addition, many forensics laboratories want to keep control of their crime scene samples in order to maintain a chain of custody for evidence in order to reduce challenges in court." The kit, officially introduced on Tuesday at the American Academy of Forensic Science meeting in New Orleans, La., is the first of its kind developed for the consumable test kit market and contains all of the reagents and protocols required for forensics laboratories around the world to perform their own ancestry analysis. Proprietary on-line software systems provided by DNAPrint(TM) are expected to enable investigators to interpret their results and relate them to the likely anthropometric (physical) features of a would-be suspect by referencing DNA samples to DNAPrint's proprietary ancestry databases. The DNAWitness(TM) kit can be utilized on capillary electrophoresis (CE) instruments commonly found in forensic and university laboratories. Starting this week, the kit will be entering beta testing at select forensics laboratories. After the testing phase, which is expected to take three to four months, the Company intends to build an inventory of kits for its distributor network and its own sales force for sale to the forensics market. The Company's testing services are available for the screening of a large number of samples or individual samples, until and even after the kit is available; investigators, forensic scientists and medical examiners need not wait until the kit is available to access this powerful new technology. DNAPrint(TM) introduced DNAWitness(TM) technology to the law enforcement community in early 2003 and immediately gained national attention when it was credited with assisting in the apprehension of a suspected serial killer in Louisiana. It currently is aiding law enforcement agencies in more than 80 criminal investigations in the United States, United Kingdom, Australia and Canada. About DNAPrint genomics, Inc. DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company's ANCESTRYby DNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com . Safe Harbor Provision All statements in this press release that are not historical are forward- looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848 SOURCE DNAPrint genomics
Contact Information: Richard Gabriel, President and CEO, DNAPrint genomics, +1-941-366-3400; or Ron Stabiner, The Wall Street Group, Inc., +1-212-888-4848, for DNAPrint genomics
posted
hey rromeo...how does that lev2 look at the moment...just saw some big buys go through at the hod ask....seems like mms are up to there old games with this....increasing the b&a spread ...etc...
-------------------- 4,311 heads are better than one...unless that one is a market maker
IP: Logged |
quote:Originally posted by iknowlessthannothing: hey rromeo...how does that lev2 look at the moment...just saw some big buys go through at the hod ask....seems like mms are up to there old games with this....increasing the b&a spread ...etc...
I know I'm replying late but your right. MM's do look like they are playing some games today. And that goes for a few other stocks that I played today.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
